Background and Aim: A subcirrhotic range of liver stiffness (sc-LS), assessed by transient elastography, is associated with better outcomes in patients with chronic hepatitis B (CHB). We investigated whether the achievement of sc-LS by antiviral therapy (AVT) reduced the risk of developing hepatocellular carcinoma (HCC) in patients with CHB-related advanced fibrosis or cirrhosis. Methods: In total, 209 patients with CHB-related advanced fibrosis or cirrhosis, who received paired transient elastography examinations during AVT between 2007 and 2012, were enrolled. The cut-off LS value for ultrasonographic cirrhosis was defined as 11.6 kPa. Results: The median age of the study population was 51 years, with males predominating (n = 138, 66.0%). The median LS value at enrollment was 14.1 kPa (interquartile range: 9.5-24.1 kPa). After 2 years of AVT, 140 (67.0%) patients achieved sc-LS. During the study period, 28 (13.4%) patients developed HCC after 2 years of AVT. On multivariate analysis, the achievement of sc-LS after AVT was independently associated with a decreased risk of HCC development (hazard ratio [HR] = 0.485, P = 0.047), whereas older age (HR = 1.071) and male gender (HR = 3.704) were independently associated with an increased HCC risk (both P < 0.05). Patients with a cirrhotic range of LS value after 2 years of AVT were at a higher risk of HCC development than those with sc-LS (log-rank test, P = 0.020). Conclusions: The achievement of sc-LS after AVT can reduce the risk of HCC development in patients with CHB, even when advanced fibrosis or cirrhosis is apparent on starting AVT.
Introduction
Chronic hepatitis B virus (HBV) infection represents a significant global medical burden, especially in Asian countries where HBV infection is endemic. 1 Globally, approximately one-third of cirrhosis cases are associated with chronic HBV infection, which can eventually lead to the development of hepatocellular carcinoma (HCC). 2 Because uncontrolled HBV replication is associated with an increased risk of cirrhosis and HCC, 3 antiviral therapy (AVT) to suppress viral replication has been the mainstay treatment strategy for chronic HBV infection. 4 The single most important risk factor for HCC development is well known to be cirrhosis, 5 which does not allow the distinction between a fibrogenic process that is in progress but potentially reversible. 6 Indeed, recent potent AVT has improved the long-term prognosis of patients with chronic hepatitis B (CHB) by facilitating regression of fibrosis or reversal of cirrhosis, thus ultimately reducing the risk of HCC development. [7] [8] [9] Therefore, dynamic assessment of fibrotic burden during AVT is of great importance for the stratification of prognosis according to AVT response. This concept is further supported by a recent study that insisted on the importance of dynamic assessment in the quality of fibrotic burden during AVT, rather than using 'conventional' staging systems focusing mainly on the severity of fibrotic burden at static time points. 10 To date, liver biopsy (LB) has been the gold standard to assess the degree of fibrotic burden in spite of pitfalls, such as invasiveness, sampling error, and interpretational variability. 11 Additionally, because most patients become asymptomatic and show normalization of laboratory findings, it is almost infeasible to perform an LB during AVT. Currently, liver stiffness (LS), assessed using transient elastography (TE), is considered an accurate and reliable surrogate for LB in the assessment of liver fibrosis. 12, 13 In addition to the high accuracy of TE in diagnosing cirrhosis, [14] [15] [16] [17] a recent study showed that TE can sensitively discriminate a subgroup with lesser risk of HCC development by identifying subcirrhotic-range LS (sc-LS), which indicates lower fibrotic burden even in patients with clinically evident CHB-related cirrhosis. 18 Thus, it is reasonable to hypothesize that noninvasive monitoring of changes in fibrotic burden during AVT could help to identify individuals with long-term favorable outcomes and apply an optimized surveillance program accordingly. Because of the absence of data regarding this issue, we performed this multicenter cohort study to investigate whether the achievement of sc-LS, assessed using TE after AVT, is associated with a reduced risk of HCC development in patients with CHB-related advanced fibrosis or cirrhosis.
Materials and methods
Patients. In total, 279 patients with CHB-related advanced fibrosis or cirrhosis, who received paired TE assessments at enrollment (initiation of AVT) and after 2 years of AVT between 2007 and 2012, were considered eligible for inclusion in this multicenter cohort study. The patients were enrolled from five tertiary institutions. Exclusion criteria were as follows: TE failure (valid shot = 0), an invalid LS value, pegylated interferon-based AVT; HCC at enrollment or past history of it; HCC development between enrollment and 6 months after the second TE assessment; previous history of liver transplantation or hepatic decompensation; coinfection with hepatitis C, hepatitis D, or HIV; significant alcohol consumption (>40 g/d) 19 ; Child-Pugh class B or C; right-sided heart failure; ascites; pregnancy; or other serious concurrent medical illness (Fig. S1) .
The study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of each institution. Written informed consent was not obtained from patients because of the retrospective nature of this multicenter cohort study.
Definitions. The diagnosis of HCC was established on the basis of the guidelines of the American Association for the Study of Liver Disease. 20 Cirrhosis was diagnosed on the basis of ultrasonographic findings suggestive of cirrhosis, including a blunted, nodular liver edge accompanied by splenomegaly (>12 cm). 21 In this study, 11.6 kPa was used to define TE-based cirrhosis, according to the results of a previous Korean multicenter study. 22 Accordingly, LS values <11.6 kPa were defined as sc-LS, whereas LS values ≥11.6 kPa were defined as cirrhotic-range LS values (c-LS). The upper limit of normal (ULN) for the alanine aminotransferase (ALT) level was defined as 40 IU/L. 21 Liver stiffness measurement using transient elastography. Transient elastography was performed by well-trained technicians or nurses (experience of more than 1000 TE examinations) at each institution. Details of the technique and examination procedure were reported previously. 23 In this study, only LS values with at least 10 validated measurements and a success rate of at least 60% were considered reliable. The median value of successful measurements was taken as representative of the LS value of a given patient only if the interquartile (IQR) to median value ratio was <0.3.
Statistical analyses. Data are expressed as the median (IQR) or n (%) as appropriate. Differences among continuous and categorical variables were examined for statistical significance using Student's t-test (or the Mann-Whitney test) and the chisquared test (or Fisher's exact test). Patients were censored at the time of HCC development or at the last follow-up. Cumulative HCC incidence rates were analyzed using the Kaplan-Meier method and compared using the log-rank test. For independent risk factors to be estimated for the achievement of sc-LS and HCC development, univariate and subsequent multivariate regression analyses were used. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were used where indicated. All statistical analyses were performed using SPSS software (ver. 18.0; SPSS Inc., Chicago, IL, USA). A P-value <0.05 was considered to indicate statistical significance.
Results
Clinical characteristics of the study population. The median interval between the initiation of AVT and baseline TE assessment was 11 days (IQR: 0-28 days). In total, 12 patients were excluded because of TE measurement failure (at enrollment or follow-up) or unreliable LS (dropout rate = 4.3% [267/279]). After excluding 58 further patients according to our exclusion criteria, we used the remaining 209 patients in the final analysis (Fig. S1) .
The follow-up TE assessment was performed after 2 years of AVT (median = 24.4 months [IQR, 18.5-30.6 months]). The clinical characteristics of the study cohort at enrollment and after 2 years of AVT are presented in Table 1 . The median age of the study population was 51 years, and males predominated (n = 138, 66.0%) at enrollment. The median body mass index (BMI) was 24.7 kg/m 2 (IQR, 22.1-25.9 kg/m 2 ). The median LS value was 14.1 kPa (IQR, 9.5-24.1 kPa), and 81 (38.8%) patients showed an sc-LS value at enrollment. AVT agents included lamivudine in 17 (8.1%), adefovir in 8 (3.8%), telbivudine in 33 (15.8%), clevudine in 4 (1.9%), entecavir in 139 (66.5%), and tenofovir in 8 (3.8%) patients. After 2 years of AVT, the proportion of patients with sc-LS increased to 67.0% (n = 140). During 2 years of AVT, the proportion of patients with high genetic barrier drugs (70.3-80.0%) increased, whereas the proportion of hepatitis B e antigen positivity (35.4-24.4%), the median aspartate aminotransferase level (37-26 IU/L), ALT level (36-24 IU/L), and LS value (14.1-8.7 kPa) all decreased.
Most patients showing sc-LS at enrollment maintained it after 2 years of AVT (n = 75 of 81, 92.6%). Additionally, around half of patients showing c-LS at enrollment achieved sc-LS after 2 years of AVT (n = 65 of 128, 50.8%) (Fig. 1) .
Comparison between patients with subcirrhotic range of liver stiffness and those with cirrhotic range of liver stiffness at enrollment and after 2 years of antiviral therapy. At enrollment, patients with sc-LS (n = 81, 38.8%) had significantly lower ALT levels (median, 33 vs 37 IU/L) and aspartate aminotransferase levels (median, 30 vs 37 IU/L), higher serum albumin levels (median, 4.3 vs 4.0 g/dL), and lower LS values (median, 8.9 vs 21.4 kPa) than patients with c-LS (n = 128, 61.2%; all P < 0.05) ( Table 2 ). Additionally, after 2 years of AVT, patients with sc-LS values (n = 140, 67.0%) had significantly lower ALT levels (median, 24 vs 33 IU/L), lower total bilirubin levels (median, 0.8 vs 1.0 mg/dL), higher serum albumin levels (median, 4.3 vs 4.1 g/dL), lower international normalized ratio levels (median, 1.03 vs 1.10), and lower LS values (median, 7.3 vs 18.4 kPa) than patients with c-LS values (n = 69, 33.3%; all P < 0.05) ( Table 2) .
Comparison between patients who developed hepatocellular carcinoma and those who did not. During the median follow-up period of 62.2 months (IQR, 54.4-71.4 months), 28 (13.4%) patients developed HCC after 2 years of AVT. The cumulative incidences of HCC at 3 and 5 years after 2 years of AVT were 9.4% and 12.1%, respectively (Fig. S2 ). The baseline characteristics of patients who developed HCC (n = 28, 13.4%) and those who did not (n = 181, 86.6%) are shown in Table 3 . Patients who developed HCC were significantly older (median, 57 vs 51 years) and significantly more likely to be males (85.7% vs 63.0%) and had lower platelet counts (median, 103 vs 131 10 9 /L) than patients who did not develop HCC (all P < 0.05) ( Table 3) .
Predictors of hepatocellular carcinoma development after 2 years of antiviral therapy. In a multivariate analysis, the achievement of sc-LS after 2 years of AVT was independently associated with a lower risk of HCC development (HR = 0.485, 95% CI 0.230-0.922, P = 0.047), whereas older age (HR = 1.071, 95% CI 1.029-1.115, P = 0.001) and male gender (HR = 3.704, 95% CI 1.282-10.703, P = 0.016) were independently associated with an increased risk of HCC development after 2 years of AVT (Table 4) . Patients with c-LS showed an increased risk of HCC development versus those with sc-LS after 2 years of AVT (log-rank test, P = 0.020) (Fig. 2) .
Subgroup analysis. In our cohort, six (2.9%) patients showed high ALT levels (>5× ULN), which might influence the TE results. 24 Thus, we selected 182 (87.1%) patients with ALT ≤2× ULN at enrollment to ensure the reliability of the TE assessment (Table S1 ). Of these, 25 (13.7%) patients showed HCC development after 2 years of AVT. In univariate analyses, older age, male gender, and higher HBV-DNA and ALT levels were significantly associated with the risk of HCC development (all P < 0.05). Multivariate analysis showed that older age (HR = 1.071, 95% CI 1.019-1.125, P = 0.007) and higher HBV-DNA level (HR = 1.000, 95% CI 1.000-1.000, P = 0.004) were positively associated with the risk of HCC development, whereas the achievement of sc-LS after 2 years of AVT was negatively associated with the risk of HCC development after 2 years of AVT (HR = 0.421, 95% CI 0.182-0.974, P = 0.043). Among patients with c-LS at baseline (n = 128, 61.2%), age was the only factor to predict HCC development after 2 years of AVT (HR = 1.072, 95% CI 1.019-1.129, P = 0.007), whereas the achievement of sc-LS after 2 years of AVT tended to reduce the risk of HCC development (HR = 0.402, 95% CI 0.142-1.133, P = 0.085).
Discussion
Although AVT reduced the risk of HBV-related HCC development, 25 HCC is not eliminated by AVT. 26 Moreover, HCC incidence in CHB patients receiving appropriate AVT is still significantly higher than that in those with inactive CHB who do not require AVT. 27 As our study showed that 28 (13.4%) patients with CHB-related advanced fibrosis or cirrhosis developed HCC after 2 years of AVT during the study period, despite receiving AVT, all these phenomena may be explained largely by the potential presence of underlying advanced fibrosis or cirrhosis. 25 Thus, identification of fibrosis regression or progression during AVT, as well as the assessment of fibrotic burden at a given time point, can help physicians establish more efficient surveillance strategies for patients with CHB-related advanced fibrosis or cirrhosis. In this regard, our study showed that TE can be useful for monitoring changes in the fibrotic burden of patients with CHB-related advanced fibrosis or cirrhosis undergoing AVT, and provided an easy-to-use therapeutic target of AVT-induced sc-LS, which was associated with better long-term outcomes (reflected by HCC development) in this study population. However, our results should be interpreted with careful cautions. Because the risk of HCC development cannot be eliminated because of the underlying fibrotic burden, appropriate surveillance should not be ignored in spite of fibrosis regression, reflected by the achievement of sc-LS after 2 years of AVT.
Similar to our study, other studies have investigated longitudinal changes in LS values in patients with CHB undergoing AVT. 12 In a Japanese study, 28 LS values decreased significantly during 12 months of entecavir therapy (median from 11.2 to 7.8 kPa). Additionally, they reported that the decrease in LS values was more likely due to fibrosis regression, with parallel decreases also seen in serum fibrosis markers, such as the amino-terminal peptide of type III pro-collagen and the type IV collagen 7S domain. A Hong Kong study also found that AVT, as well as normalization of ALT levels, was independently associated with a significant decrease in LS values after 3 years of AVT (mean from 7.3 to 6.1 kPa). 29 Another Japanese study showed that LS values decreased continuously and significantly from baseline compared with at 1, 2, and 3 years after AVT (median from 12.9 to 7.5 to 6.5 to 4.7 kPa, respectively), whereas LS values tended to increase in patients without AVT (from 6.1 to 6.3 kPa after a median interval of 422 days). 30 Although we focused on high-risk patients with CHB-related advanced fibrosis or cirrhosis, who might be expected to benefit most from the reversal of fibrotic burden, the findings of our study, and of these previous studies, support that AVT in patients with CHB is associated with a significant decrease in LS values. , group with sc-LS.
The clinical importance of sc-LS among patients with CHBrelated cirrhosis was recently proposed in a report by Jeon et al. 18 Similar to our study, 39.6% of their study population showed sc-LS, which was an independent protective factor against HCC development (HR = 0.462). Furthermore, the cumulative HCC incidence was significantly lower for patients with sc-LS than for those with c-LS. However, in that work, heterogeneous patients with and without AVT composed the study population and AVT was not selected as an independent predictor of HCC development. Thus, there is a possibility of inherent differences in the characteristics of patients who received AVT (replicative or reactivated CHB) versus those who did not (inactive or immune tolerant CHB), and the influence of AVT on the risk of HCC development might not have been assessed accurately. In contrast, our study focused only on patients with CHB-related advanced fibrosis or cirrhosis who initiated AVT at enrollment, which might enable us ascertain the clinical implication of sc-LS in this homogeneous study population, with no confounding influence of AVT on the risk of HCC development. Furthermore, we tried to control for overestimation of the influence of a high ALT level on the TE assessment by selecting only patients with an ALT level <2× ULN in subgroup analysis 24 and found a similar prognostic value of sc-LS for the prediction of HCC development in this subcohort. However, because the median ALT level was relatively low (median = 36 IU/L), which might have attenuated the influence of a high ALT level on TE, further studies should confirm whether sc-LS in patients with CHB-related advanced fibrosis or cirrhosis undergoing AVT can be prognostic, regardless of the wide range of ALT levels.
It is known that a premature TE assessment, that is, earlier than 6 months after the end of therapy, does not seem to accurately reflect fibrosis regression, but rather a decrease in necroinflammation 31 ; at least 6 months is required for the stabilization of necroinflammation due to HBV exacerbation to obtain an accurate reflection of fibrotic burden by TE assessment. 32 Additionally, it is known that a significant decrease in LS can be detected only after 1.5-3 years of follow-up subsequent to a sustained virological response in patients with chronic hepatitis C. 6 These findings suggest that the reduction in LS value that we observed in our study, reaching the subcirrhotic range after about 2 years of AVT, might reflect actual changes in fibrotic burden in spite of histological information. However, because a recent study showed that TE sensitivity was too low (61%) to be used clinically as evidence of cirrhosis regression, on the basis of paired biopsy information (pretreatment and post-treatment) for CHC, 33 the results of our study should be interpreted with caution. Additionally, several studies have reported that a decrease in LS in patients with CHB undergoing AVT did not reflect actual regression of fibrotic burden but rather improved necroinflammation. 19, 34 However, the differences in fibrotic burden between these studies and ours (full spectrum of CHB vs advanced fibrosis or cirrhosis only) might in part explain the differing results.
Several issues remain unresolved from our study. First, histological data were not available, probably because all of the study participants showed ultrasonographic evidence suggestive of advanced fibrosis or cirrhosis and thus did not need to undergo an LB to confirm the presence of advanced fibrosis or cirrhosis. Accordingly, we could not be sure whether the achievement of sc-LS was attributable to an improvement in necroinflammation, regression of fibrotic burden, or both. However, because both regression of liver fibrosis and stabilization of necroinflammation are associated with a reduced risk of HCC development, 35 the close association between the decrease in LS value (reflecting improvement in these two factors), and the reduced risk of HCC development does not seem surprising, which suggests the potential for LS values to act as a comprehensive surrogate for hepatic status. Second, although we tried to recruit more study participants using a multicenter design to enhance statistical reliability, the overall sample size was not large enough to stratify our study population into varying subgroups, to test the predictive value of sc-LS after AVT in each subgroup. This small sample size of our study might be related to the borderline statistical significance of the achievement of sc-LS in a subgroup with c-LS at baseline. In addition, the number of patients with HCC development was small (n = 28, 13.4%), which also might explain why well-known predictors, such as male gender and LS value, did not independently predict HCC development. 5, 13 Third, it is known that a learning curve is involved when obtaining reproducible TE results. Although all of the technicians and nurses in our multicenter study who performed the TE assessments had sufficient experience, inter-institutional variability might have confounded the results. 36 In addition, relatively small sample sizes from three institutions (n < 25) may have biased the final results. Although the exact reason is not clear, this potential selection bias might explain why the significant difference in HCC development between c-LS and sc-LS groups diverged only after around 3 years of AVT in our cohort. In addition, this phenomenon can be explained in part by a recent study by Papatheodoridis et al. that showed that the HCC risk is decreasing beyond year 5 of entecavir/tenofovir therapy in patients with CHB, particularly in those with compensated cirrhosis. 37 Finally, the rate of TE assessment failure or an unreliable LS value (4.3%) was similar to those of other Asian studies (1.1-3.5%), 38 but much lower than that in a recent large European study. 39 Although the exact reason for this is unclear, lower BMI (median = 24.7 kg/m 2 , 2.4% with a BMI ≥30 kg/m 2 [5/209] ) in our study may in part explain this phenomenon.
In conclusion, we showed that the achievement of sc-LS after 2 years of AVT can reduce the risk of HCC development in patients with CHB, even when advanced fibrosis or cirrhosis is apparent on initiation of AVT. Our results may help physicians to modify surveillance strategies according to on-treatment LS responses to AVT in this population. However, further studies are needed to define more precisely the role of noninvasive methods in monitoring fibrosis regression and to confirm that incorporation of TE into the surveillance strategy during AVT is beneficial and cost-effective. Figure S1 . Flow chart of selecting the study population. HBV, hepatitis B virus; TE, transient elastography; AVT, antiviral therapy; LS, liver stiffness; HCC, hepatocellular carcinoma. Figure S2 . Cumulative incidence of HCC in the study population. During the median follow-up period of 62.2 months (interquartile range, 54.4-71.4 months), 28 (13.4%) patients developed HCC after 2 years of AVT. The cumulative incidences of HCC at 3 and 5 years after 2 years of AVT were 9.4% and 12.1%, respectively. HCC, hepatocellular carcinoma; AVT, antiviral therapy.
